Aurora Cannabis to Spotlight Strategy at TD Cowen Conference, Closes Bevo Deal
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurora Cannabis ( (TSE:ACB) ) has provided an announcement.
Aurora Cannabis will showcase its growth strategy and view on global medical cannabis trends at TD Cowen’s 46th Annual Health Care Conference in Boston on March 2, 2026, where CFO Simona King will join a fireside chat and investor meetings. The presentation is positioned to highlight the company’s international leadership, Canadian manufacturing capabilities and the broader market forces shaping the sector, reinforcing Aurora’s profile among institutional investors.
The company also confirmed it has closed its previously announced transaction with Bevo Agtech, advancing a deal that may support operational diversification and potential synergies across cultivation and plant science. Completion of the Bevo transaction underscores Aurora’s ongoing efforts to refine its portfolio and strengthen its competitive positioning in the evolving global cannabis market.
The most recent analyst rating on (TSE:ACB) stock is a Hold with a C$4.50 price target. To see the full list of analyst forecasts on Aurora Cannabis stock, see the TSE:ACB Stock Forecast page.
Spark’s Take on TSE:ACB Stock
According to Spark, TipRanks’ AI Analyst, TSE:ACB is a Neutral.
The score is held back primarily by weak cash-flow quality and poor technical momentum (price below key moving averages with bearish MACD). Offsetting factors include an improving operational trajectory with strong gross margins, a relatively manageable balance sheet, and a constructive earnings outlook centered on growing higher-margin global medical cannabis.
To see Spark’s full report on TSE:ACB stock, click here.
More about Aurora Cannabis
Aurora Cannabis Inc., listed on the NASDAQ and TSX under the symbol ACB, is a Canadian-based global leader in medical cannabis. The company serves medical and consumer markets in Canada, Europe, Australia and New Zealand, focusing on high-margin, medical-first opportunities supported by GMP-certified facilities in Canada and Germany and a portfolio of brands including Aurora, MedReleaf and Pedanios.
Average Trading Volume: 570,075
Technical Sentiment Signal: Sell
Current Market Cap: C$276.2M
See more data about ACB stock on TipRanks’ Stock Analysis page.
